IMNN

Business Context and Reporting Period

Company: Celsion Corporation (Note: Input metadata referenced "Imunon, Inc.", but the filing text identifies the registrant as Celsion Corporation).

Reporting Period: Fiscal year ended September 30, 2001.

Business Overview: Celsion is a research and development company developing medical treatment systems using minimally invasive focused heat technology. Primary product candidates include a Microwave Uretheroplasty system for Benign Prostatic Hyperplasia (BPH) and a second-generation system for breast cancer treatment. The company also holds licenses for heat-sensitive liposomes (Duke University) and heat-activated gene therapy compounds (Sloan-Kettering).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: The company generated no revenue in 2001 compared to $3,420 in 2000 (parts sales for legacy equipment).
• Increased Operating Loss: Net loss increased by approximately 52% to $6.9 million, driven by a 82% increase in R&D expenses and a 21% increase in SG&A expenses.
• Cash Burn: Cash and cash equivalents decreased by approximately $6.3 million (from $8.8M to $2.5M) due to funding ongoing clinical trials and operations.
• R&D Focus: The surge in R&D spending was attributable to pivotal Phase II clinical trials for both BPH and breast cancer systems, as well as the initiation of heat-activated liposome development.

Guidance, Outlook, and Risks

Outlook and Management Commentary

• Product Timeline:
  • BPH System: Phase II trials (160 patients) completed as of November 29, 2001. Two of three PMA modules submitted to FDA; final clinical data module expected Q2 2002. Marketing anticipated Summer 2002 if approved.
  • Breast Cancer System: Phase II trials underway; completion expected by end of calendar 2002. Marketing anticipated before end of 2003.
  • Liposomes/Gene Therapy: Pre-clinical stages. IND application for liposomes expected Q1 2002; IND for gene therapy expected end of 2003.
• Capital Needs: Management expects to expend approximately $7 million in fiscal 2002. The company relies on equity financing to fund operations.
• Recent Financing: A private placement initiated December 13, 2001, raised net proceeds of approximately $3.7 million as of December 20, 2001. Management believes current resources plus this financing will fund operations through fiscal 2002.

Risks and Contingencies

• Liquidity Risk: The company has a history of significant losses and an accumulated deficit of $33.6 million. Continued profitability depends on successful commercialization, which is not guaranteed.
• Regulatory Risk: Success depends on FDA approval for Class III medical devices and new drug applications. Delays or rejections would prevent revenue generation.
• Licensing Risk: The business depends on exclusive licenses from MIT, MMTC, Duke University, and Sloan-Kettering. Failure to meet milestones could result in loss of rights.
• Legal Proceedings: Ongoing litigation with a former director regarding warrant rescission. Defendants filed a counterclaim; insurance carrier denied liability for these claims.
• Delisting Risk: Due to sustained losses and low stock price, the company faces potential delisting from the American Stock Exchange.

Investor Verification Checklist

• Cash Runway: Verify if the $3.7M raised in the private placement (plus existing cash) is sufficient to cover the projected $7M fiscal 2002 burn rate without further dilution.
• FDA Status: Confirm the status of the BPH PMA application submission and the timeline for the breast cancer Phase II trial completion.
• Litigation Exposure: Assess the potential financial impact of the counterclaim filed by the former director, given the denial of insurance coverage.
• Licensing Milestones: Review the specific performance milestones in the Duke and Sloan-Kettering agreements to ensure the company is not in breach.
• Stock Price Volatility: Monitor stock price relative to the $5.00 threshold for "penny stock" rules and the American Stock Exchange listing requirements.